Aeson Therapeutics Inc.

Dehydroepiandrosterone (DHEA) may have therapeutic uses against cardiovascular disease, immune disorders, cancer and other diseases, but the hormone is a precursor of androgens and estrogens and can cause undesirable side effects.

RCT formed Aeson Therapeutics to develop fluasterone, a synthetic steroid that may be more effective than DHEA without the adverse side effects. Fluasterone development targets include treatment of lipid disorders, inflammatory diseases and as a cancer chemoprevention agent.

RCT and other investors provided funding for Aeson's initial development. Hollis-Eden Pharmaceuticals (NASDAQ:HEPH) in San Diego acquired Aeson in May 2006.

Company overview

Download PDF (150kb)

Inventor/Founder

Arthur G. Schwartz, Ph.D., and colleagues, Temple University

Aeson Contact

Chad Souvignier, Ph.D. RCT Director